Patent risk isnt just a legal issueits a board-level risk.
In pharma, IP litigation can feel like a distant storm: a flurry of filings, expert declarations, and courtroom dates that executives watch from the sidelines. But for boards, the question is…

Designing around formulation patents isnt just legal strategyits product strategy.
If youre a generic developer, formulation patents can feel like an immovable wall: a narrow claim, a specific composition, a particular method of makingyet the practic…

Pharma forensics is having a momentand its not just for patent attorneys.
In the last few years, the industry has gotten better at one thing: filing. But it hasnt gotten better at reading. That gap is where competitive advantage hides.
If you want to u…

Generic developers dont lose to the patentthey lose to the moat.
In the early days of generic competition, the playbook was simple: find the weak point in the primary patent, file the ANDA, and move on. But the market has evolved. Brand strategies in…

Patent cliffs arent just a legal eventtheyre a supply-chain stress test.
If youre building inventory plans, negotiating contracts, or forecasting demand for blockbuster therapies, the phrase patent cliff can sound abstractuntil it hits your network lik…

Most patent searches miss the real story.
If youve ever run a keyword-only prior art search, youve probably felt the same frustration: you find what youre looking forbut you dont find what you should be looking for. In chemical and biologic patents, …

Pharma IP isnt just about having patentsits about surviving them.
If youre developing a drug and your competitors formulation patent is looming, youre not just facing a legal hurdle. Youre facing a strategic design constraint that can determine wheth…

Most people read drug patents like legal documents. Formulation forensics reads them like a crime scene.
If youve ever wondered why two similar formulations can behave so differently in the real worldbioavailability, stability, manufacturability, even …

The biosimilar patent dance isnt a formalityits the first move in a multi‑year chess match.
If youre a biologics innovator or a biosimilar applicant, the stakes are obvious: exclusivity, market timing, and the ability to launch on schedule. Whats l…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is less about luck and more about execution: timing, litigation strateg…